Answers are grounded in this paper and cite their sources.
Background People living with human immunodeficiency virus (PLHIV) have a 25-35–fold higher chance of being diagnosed with squamous-cell carcinoma of the anal canal (SCAC). Patients and methods We prospectively evaluated the safety and efficacy of retifanlimab in PLHIV and SCAC enrolled in the POD1UM-202 and POD1UM-303/InterAACT-2 studies; PLHIV with CD4+ cell count ≥200/μl and undetectable viral load were enrolled and continued on highly active antiretroviral therapy (HAART). HIV viral load and CD4+ cell counts were assessed every 8 weeks and could be reduced to every 6 months during safety and disease follow-up. Results Among the 20 patients with HIV enrolled, median age was 58 years, 70% were male, and 80% white. Nine patients received retifanlimab monotherapy and six patients received retifanlimab + platinum-based chemotherapy; five patients received placebo + chemotherapy. No consistent overall trend in CD4+ cell counts or loss of HIV control was observed; no treatment-emergent opportunistic infections were recorded. Immune-related adverse events were consistent among patients without HIV. Efficacy was broadly consistent across the overall study populations. Patient-reported outcomes showed no negative impact. Retifanlimab pharmacokinetics were independent of HIV status and not impacted by HAART. Conclusions This prospective evaluation, the first in PLHIV and SCAC, demonstrates that the efficacy of retifanlimab is qualitatively consistent with that in HIV-negative patients with no excess toxicity or reduced HIV control, supporting the inclusion of HIV-positive patients in immunotherapy trials.
No takes yet. Share an insight, caveat, or question.
Spano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: